Patients with hematologic cancers are more vulnerable to COVID-19 compared to patients with solid cancers

Başçı, Semih; Ata, Naim; Altuntaş, Fevzi; Yiğenoğlu, Tuğçe Nur; Dal, Mehmet Sinan; Korkmaz, Serdal; Namdaroğlu, Sinem; Baştürk, Abdulkadir; Hacıbekiroğlu, Tuba; Doğu, Mehmet Hilmi; Berber, İlhami; Dal, Kürşat; Erkurt, Mehmet Ali; Turgut, Burhan; Çelik, Osman; Ülgü, Mustafa Mahir; Birinci, Şuayıp

doi:10.1007/s11739-021-02784-y

Cited by 15 publications

(12 citation statements)

References 14 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In our patients with CML, the prevalence of Covid‐19 infections did not differ significantly from the general Austrian population as well. Such a low prevalence of Covid‐19 infections among patients with CML was also reported in several other papers 38,39,43,44 . Of note, most of these CML patients were in chronic phase and/or had a stable course in response to TKIs 43,47,48 .…”

Section: Discussionsupporting

confidence: 61%

Section: Discussionmentioning

confidence: 99%

“…Published data report a higher risk for Covid‐19 infections in patients with certain hematologic neoplasms as compared to the general population or patients with solid tumors. 36 , 37 , 38 , 39 , 40 , 41 Such diseases were acute leukemia, advanced MDSs, or lymphomas. 22 , 27 , 39 , 40 , 41 In contrast, other hematologic malignancies including myeloproliferative neoplasms might be a protective factor.…”

Section: Discussionmentioning

confidence: 99%

See 2 more Smart Citations

Incidence of symptomatic Covid‐19 infections in patients with mastocytosis and chronic myeloid leukemia: A comparison with the general Austrian population

Graf

Herndlhofer

Kundi

et al. 2022

European J of Haematology

View full text Add to dashboard Cite

Background:The SARS-COV-2 (Covid-19) pandemic has impacted the management of patients with hematologic disorders. In some entities, an increased risk for Covid-19 infections was reported, whereas others including chronic myeloid leukemia (CML) had a lower mortality. We have analyzed the prevalence of Covid-19 infections in patients with mastocytosis during the Covid-19 pandemic in comparison to data from CML patients and the general Austrian population. Materials and Methods: The prevalence of infections and PCR-proven Covid-19 infections was analyzed in 92 patients with mastocytosis. As controls, we used 113 patients with CML and the expected prevalence of Covid-19 in the general Austrian population. Results: In 25% of the patients with mastocytosis (23/92) signs and symptoms of infection, including fever (n = 11), dry cough (n = 10), sore throat (n = 12), pneumonia (n = 1), and dyspnea (n = 3) were recorded. Two (8.7%) of these symptomatic patients had a PCR-proven Covid-19 infection. Thus, the prevalence of Covid-19 infections in mastocytosis was 2.2%. The number of comorbidities, subtype of mastocytosis, regular exercise, smoking habits, age, or duration of disease at the time of interview did not differ significantly between patients with and without Covid-19 infections. In the CML cohort, 23.9% (27/113) of patients reported signs and symptoms of infection (fever, n = 8; dry cough, n = 17; sore throat, n = 11; dyspnea, n = 5). Six (22.2%) of the symptomatic patients had a PCR-proven Covid-19 infection. The prevalence of Covid-19 in all CML patients was 5.3%. The observed number of Covid-19 infections neither in mastocytosis nor in CML patients differed significantly from the expected number of Covid-19 infections in the Austrian population. Conclusions: Our data show no significant difference in the prevalence of Covid-19 infections among patients with mastocytosis, CML, and the general Austrian population and thus, in mastocytosis, the risk of a Covid-19 infection was not increased compared to the general population.

show abstract

Section: Discussionsupporting

confidence: 61%

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Incidence of symptomatic Covid‐19 infections in patients with mastocytosis and chronic myeloid leukemia: A comparison with the general Austrian population

Graf

Herndlhofer

Kundi

et al. 2022

European J of Haematology

View full text Add to dashboard Cite

show abstract

“…From 1871 identified references, a total of 67 studies accounting for 10,061 hematological patients and 111,143 controls were included in the systematic review (Table S3 summarizes the included studies and reported outcomes). 13 , 15 , 17 , 18 , 19 , 20 , 21 , 22 , 23 , 24 , 25 , 26 , 27 , 28 , 29 , 30 , 31 , 32 , 33 , 34 , 35 , 36 , 37 , 38 , 39 , 40 , 41 , 42 , 43 , 44 , 45 , 46 , 47 , 48 , 49 , 50 , 51 , 52 , 53 , 54 , 55 , 56 , 57 , 58 , 59 , 60 , 61 , 62 , 63 , 64 , 65 , 66 , 67 , 68 , ...…”

Section: Resultsmentioning

confidence: 99%

Predictors of clinical evolution of SARS‐CoV‐2 infection in hematological patients: A systematic review and meta‐analysis

Carrara

Razzaboni

Azzini

et al. 2022

Hematological Oncology

View full text Add to dashboard Cite

Main aim of this systematic review is to quantify the risk and identify predictors of clinical evolution of SARS‐CoV‐2 in hematological patients compared to different control populations. Two independent reviewers screened the literature assessing clinical outcomes of SARS‐CoV‐2 infection in adult patients with active hematological malignancies published up to June 2021. Primary outcome was COVID‐19 related mortality, secondary outcomes were hospital and intensive‐care admission, mechanical ventilation (MV), and thromboembolic events. Variables related to study setting, baseline patients' demographic, comorbidities, underlying hematological disease, ongoing chemotherapy, COVID‐19 presentation, and treatments were extracted. A total of 67 studies including 10,061 hematological patients and 111,143 controls were included. Most of the studies were retrospective cohorts (51 studies, 76%) and only 19 (13%) provided data for a control group. A significant increased risk of clinical progression in the hematological population compared to the controls was found in terms of COVID‐19 related mortality (OR, 2.12; 95% CI, 1.77–2.54), hospitalization (OR, 1.98; 95% CI, 1.15–3.43), intensive‐care admission (OR, 1.77; 95% CI, 1.38–2.26), and MV (OR, 2.17; 95% CI, 1.71–2.75). The risk remained significantly higher in the subgroup analysis comparing hematological patients versus solid cancer. Meta‐regression analysis of uncontrolled studies showed that older age, male sex, and hypertension were significantly related to worse clinical outcomes of COVID‐19 in hematological population. Older age and hypertension were found to be associated also to thromboembolic events. In conclusion, hematological patients have a higher risk of COVID‐19 clinical progression compared to both the general population and to patients with solid cancer.

show abstract

“…4,5 Previous research revealed that patients with hematologic cancers (HC) experienced more severe COVID-19 symptoms and higher CFR (case fatality rate) side to those with solid cancers (SC). 6 More severe manifestation and higher CFR are found in hematologic cancer patients compared to solid cancer patients.…”

Section: Introductionmentioning

confidence: 99%

Clinical outcomes of COVID-19 patients with solid and hematological cancer: a meta-analysis and systematic review

Wahyuhadi¹,

Rusdi

Ranuh

et al. 2022

F1000Res

View full text Add to dashboard Cite

Background: Previous research has consistently shown the significant difference in outcome between cancerous and non-cancerous patients with coronavirus disease 2019 (COVID-19). However, no studies have compared the clinical manifestation of COVID-19 in hematologic cancers patients and solid cancers patients. Therefore, we analyzed the outcome of COVID-19 patients with hematological cancer and primary solid cancer worldwide through a meta-analysis and systematic review. Methods: This meta-analysis and systematic review included English language articles published between December 2019 – January 2021 from Pubmed and Google Scholar. The Newcastle Ottawa Score was used to assess the quality and bias of included studies. The outcome measures were case-fatality rate and critical care events for COVID-19 patients with cancer and comorbidities. Results: The initial search found 8910 articles, of 20 were included in the analysis. Critical care events and mortality were higher in the hematological than primary solid cancer group (relative risk (RR)=1.22 & 1.65; p <0.001). Conversely, mortality was lower in patients with two or fewer comorbidities (RR=0.57; p<0.001) and patients under the 75-year-old group (RR=0.53; p< 0.05). Conclusions: Hematologic malignancy, age, and the number of comorbidities are predictor factors for worse prognosis in COVID-19 infection.

show abstract

Patients with hematologic cancers are more vulnerable to COVID-19 compared to patients with solid cancers

Cited by 15 publications

References 14 publications

Incidence of symptomatic Covid‐19 infections in patients with mastocytosis and chronic myeloid leukemia: A comparison with the general Austrian population

Incidence of symptomatic Covid‐19 infections in patients with mastocytosis and chronic myeloid leukemia: A comparison with the general Austrian population

Predictors of clinical evolution of SARS‐CoV‐2 infection in hematological patients: A systematic review and meta‐analysis

Clinical outcomes of COVID-19 patients with solid and hematological cancer: a meta-analysis and systematic review

Contact Info

Product

Resources

About